Dabigatran versus warfarin in patients with atrial fibrillation.

Connolly, Stuart J.; Ezekowitz, Michael D.; Yusuf, Salim; Eikelboom, John; Oldgren, Jonas; Parekh, Amit; Pogue, Janice; Reilly, Paul A; Themeles, Ellison; Varrone, Jeanne; Wang, Susan; Alings, Marco; Xavier, Denis; Zhu, Jun; Diaz, Rafael; Lewis, Basil S; Darius, Harald; Diener, Hans-Christoph; Joyner, Campbell D; Wallentin, Lars

doi:10.1056/NEJMoa0905561

Record: found
Abstract: found
Article: not found

Dabigatran versus warfarin in patients with atrial fibrillation.

Author(s): Stuart Connolly, Michael Ezekowitz, Salim Yusuf, John Eikelboom, Jonas Oldgren, Amit Parekh, Janice Pogue, Paul Reilly, Ellison Themeles, Jeanne Varrone, Susan Wang, Marco Alings, Denis Xavier, Jun Zhu, Rafael Diaz, Basil Lewis, Harald Darius, Hans-Christoph Diener, Campbell D Joyner, Lars Wallentin

Publication date: 2009-09-17

Journal: The New England journal of medicine

Publisher: Massachusetts Medical Society

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor.

Related collections

Author and article information

Journal

PubMed ID:: 19717844

DOI:: 10.1056/NEJMoa0905561

Data availability:

Comments

Comment on this article

scite_

Dabigatran versus warfarin in patients with atrial fibrillation.

Read this article at

Procedural speed in criminal law

Journal

Comment on this article